Back to Search
HOWARD BURRIS, M.D.
M.D.
Medical Oncology Physician
NPI: 1417992397IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
28860(TN)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE
Class of 1985
Research & Publications (20)
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
PMID 19680296·Oncogene·2009
6-review
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
PMID 18378539·Oncologist·2008
6-review
Preclinical investigations with epothilones in breast cancer models.
PMID 18410795·Semin Oncol·2008
6-review
Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
PMID 16638456·Semin Oncol·2006
6-review
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
PMID 15793221·Oncologist·2005
3-trial
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
PMID 15955900·J Clin Oncol·2005
3-trial
Recent updates on the role of chemotherapy in pancreatic cancer.
PMID 16143160·Semin Oncol·2005
6-review
Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
PMID 15163842·Oncologist·2004
6-review
Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
PMID 15117984·J Clin Oncol·2004
3-trial
Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
PMID 11301373·Semin Oncol·2001
6-review
Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
PMID 10810934·Semin Oncol·2000
6-review
Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.
PMID 10697030·Semin Oncol·2000
3-trial
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.
PMID 19281729·Int J Clin Pharmacol Ther·2009
3-trial
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
PMID 19288572·Cancer·2009
3-trial
Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
PMID 19299236·Clin Breast Cancer·2009
3-trial
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
PMID 19318484·Clin Cancer Res·2009
3-trial
Analysis of long-term measurements of laser propagation over the Chesapeake Bay.
PMID 19381192·Appl Opt·2009
8-other
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
PMID 19661042·Clin Breast Cancer·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 250 25TH AVE N, STE 100
NASHVILLE, TN 37203 - Phone
- (615) 320-5090
Quick Facts
- NPI
- 1417992397
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 41
- Publications
- 20
Are you this provider?
Claim Your Profile